Study Finds Overwhelming Evidence That Color Blindness Hinders Learning in School, Reports EnChroma
EnChroma – creators of glasses for color blindness – today released the results of a landmark study that clearly demonstrates the negative effect color blindness has on learning for millions of students. The data strongly indicates that schools are failing to identify color blind students and that parents, educators and legislators need to better support these students.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211025005173/en/
Standard Color Vision and Color Blind View @EnChroma
In early 2020, nearly 1,000 color blind people, including the parents of color blind children, shared their opinions about how Color Vision Deficiency (CVD) affected their educational experiences. Seventy-eight percent said they were often frustrated or confused by colors in school assignments and activities. One in three say color blindness affected their confidence in school, and 30% felt like they might be a “slow learner” before discovering they’re color blind.
A contributing factor is the lack of testing for color blindness in schools. According to EnChroma, only 11 of 50 states test for CVD. As a result, many students do not realize they’re color blind. In fact, nearly half of color blind people said they didn’t learn they’re color blind until after 7th grade, almost one in three while in high school or later, and one in five don’t find out until after high school or college.
“The evidence is overwhelming that color blindness creates learning challenges for color blind students and that parents, educators, and politicians must become more aware of the prevalence of color vision deficiency, and its impact, and take action,” said Erik Ritchie, CEO of EnChroma. “Too many kids go deep into their educations without the student, their parents or teachers knowing they’re color blind. Testing for color blindness has to become universal in schools in all states and countries, and learning materials adapted to accommodate and create a level playing field for CVD students.”
One in 12 men (8%) and one in 200 women (.5%) are color blind – 13 million in the US, 30 million in Europe, and 350 million worldwide. For them, understanding colorful information in school, at work and in daily life can cause obstacles. While people with normal color vision see over one million shades of color, the color blind only see an estimated 10% of hues and shades. Common color confusions include green and yellow, gray and pink, purple and blue, and red and brown, with colors appearing muted and dull. Since 80% of information is conveyed visually, this creates issues for color blind students.
Numerous renowned universities plan to offer EnChroma glasses to color blind students to borrow on their campuses, and to educate staff to adapt materials to accommodate CVD students. They include Boston University, North Carolina State University, Alfred University and Francis Marion University, with others joining soon.
Click here for more images of how the color blind see colors.
“A teacher discovered I was color blind in the third grade. Up to that point I was often referred to as “stupid” because I couldn’t color primary colors correctly,” said one color blind survey respondent. Another relayed: “I was unable to pass chromatography lessons in organic chemistry because I couldn't distinguish the colors accurately. I had to drop the class and eventually change majors.”
Highlights from the EnChroma survey include:
- Four out of ten color blind students try to avoid schoolwork and activities involving color, and nearly half are less interested in painting, drawing, nature walks and field trips to art museums
- More than 1 in three color blind people say teachers got frustrated with them when they couldn’t understand schoolwork involving color
- Only one in four parents tell teachers that their child is color blind, and only 20% of teachers adapt schoolwork to accommodate color vision deficient students
- 81% believe teachers should adapt teaching materials for color blind students
- 87% support mandatory testing of schoolchildren for color vision deficiency
- One in four were teased by classmates or teachers due to being color blind
- Two of three parents worry about color blindness affecting their child’s education
EnChroma encourages schools to quickly and easily test students in under two minutes for color blindness via our free online test available here and at enchroma.com. To read comments from color blind respondents about their educational experiences click here.
EnChroma Color Accessibility Program
EnChroma is the lead advocate for “color accessibility” through its EnChroma Color Accessibility Program. The program helps public venues, schools, state parks, libraries, museums, and other organizations purchase and loan EnChroma glasses to color blind students and guests to help make schoolwork that involves color, colorful exhibits, attractions and/or experiences accessible to the CVD. In addition to our free color blindness test, EnChroma also offers materials for schools to share with teachers, parents and students to educate them about color blindness, its effects, and how to support color blind students. EnChroma offers a similar program for employers.
EnChroma glasses are engineered with special optical filters that help the color blind see an expanded range of colors more vibrantly, clearly and distinctly. A recent study by the University of California, Davis, and France’s INSERM Stem Cell and Brain Research Institute, demonstrated the effectiveness of EnChroma glasses.
Media: Product shots, images and interactive GIFs illustrating the challenges to learning for those with color vision deficiencies can be downloaded here. EnChroma’s CEO, survey respondents, and university and K-12 educators and parents, are available for interviews. Of the nearly 1,000 respondents to the survey, nearly three-fourths are color blind (740) and the other 247 the parents of color blind children.
About EnChroma
Based in Berkeley, Calif., EnChroma produces leading-edge eyewear for color blindness and low vision, and other solutions for color vision, sold online and through Authorized Retailers worldwide. Invented in 2010, EnChroma’s patented eyewear combines the latest in color perception, neuroscience and lens innovation to improve the lives of people with color vision deficiency around the world. EnChroma received an SBIR grant from the National Institutes of Health (NIH). It earned the 2016 Tibbetts Award from the U.S. Small Business Administration in recognition of the firm’s innovative impact on the human experience through technology, and the 2020 Innovation Award in Life Sciences from the Bay Area’s East Bay Economic Development Alliance. For more information call 510-497-0048 or visit enchroma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211025005173/en/
Contact information
Kent Streeb
Vice President, Communications & Partnerships
P: 530.908.9225
kent@enchroma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t
Qualcomm Announces Quarterly Cash Dividend17.10.2025 16:00:00 EEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom